Team:KAIST Korea

From 2013.igem.org

(Difference between revisions)
Line 1: Line 1:
 +
<!DOCTYPE HTML>
<html>
<html>
<head>
<head>
-
<meta http-equiv="refresh" content="1;url=https://dl.dropboxusercontent.com/u/202315040/igem/index.html">
+
<title>iGEM Team : KAIST_Korea</title>
-
</head>
+
<meta http-equiv="content-type" content="text/html; charset=utf-8" />
 +
<meta name="description" content="" />
 +
<meta name="keywords" content="" />
 +
<noscript>
 +
<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/202315040/igem/css/5grid/core.css" />
 +
<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/202315040/igem/css/5grid/core-desktop.css" />
 +
<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/202315040/igem/css/5grid/core-1200px.css" />
 +
<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/202315040/igem/css/5grid/core-noscript.css" />
 +
<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/202315040/igem/css/style.css" />
 +
<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/202315040/igem/css/style-desktop.css" />
 +
</noscript>
 +
 
 +
<script src="https://dl.dropboxusercontent.com/u/202315040/igem/css/5grid/jquery.js"></script>
 +
<script src="https://dl.dropboxusercontent.com/u/202315040/igem/css/5grid/init.js"></script>
 +
<!--[if IE 9]><link rel="stylesheet" href="css/style-ie9.css" /><![endif]-->
 +
</head><body>
 +
 
 +
<script type="text/javascript" src="http://ajax.googleapis.com/ajax/libs/jquery/1.4.2/jquery.min.js"></script>
 +
<script type="text/javascript" src="https://dl.dropboxusercontent.com/u/202315040/igem/jquery.easing.1.3.js"></script>
 +
     
 +
 
 +
<style>
 +
/* Reset */
 +
.menu,
 +
.menu ul,
 +
.menu li,
 +
.menu a {
 +
margin: 0;
 +
padding: 0;
 +
border: none;
 +
outline: none;
 +
}
 +
 
 +
#bar{
 +
 +
background: #4c4e5a;
 +
background: -webkit-linear-gradient(top, #4c4e5a 0%,#2c2d33 100%);
 +
background: -moz-linear-gradient(top, #4c4e5a 0%,#2c2d33 100%);
 +
background: -o-linear-gradient(top, #4c4e5a 0%,#2c2d33 100%);
 +
background: -ms-linear-gradient(top, #4c4e5a 0%,#2c2d33 100%);
 +
background: linear-gradient(top, #4c4e5a 0%,#2c2d33 100%);
 +
margin: 30px auto 0 auto;
 +
 +
}
 +
 
 +
/* Menu */
 +
.menu {
 +
height: 50px;
 +
weight: 100%;
 +
padding-left: 30%;
 +
 
 +
 +
 +
 
 +
background: #4c4e5a;
 +
background: -webkit-linear-gradient(top, #4c4e5a 0%,#2c2d33 100%);
 +
background: -moz-linear-gradient(top, #4c4e5a 0%,#2c2d33 100%);
 +
background: -o-linear-gradient(top, #4c4e5a 0%,#2c2d33 100%);
 +
background: -ms-linear-gradient(top, #4c4e5a 0%,#2c2d33 100%);
 +
background: linear-gradient(top, #4c4e5a 0%,#2c2d33 100%);
 +
margin: 30px auto 0 auto;
 +
 +
}
 +
 
 +
.menu li {
 +
position: relative;
 +
list-style: none;
 +
margin: 0px auto 0 auto;
 +
float: left;
 +
display: block;
 +
height: 50px;
 +
}
 +
 
 +
/* Links */
 +
 
 +
.menu li a {
 +
margin:0px auto;
 +
display: block;
 +
padding: 0 14px;
 +
margin: 6px 0;
 +
line-height: 40px;
 +
text-decoration: none;
 +
 +
border-left: 1px solid #393942;
 +
border-right: 1px solid #4f5058;
 +
 
 +
font-family: Helvetica, Arial, sans-serif;
 +
font-weight: bold;
 +
font-size: 18px;
 +
 
 +
color: #f3f3f3;
 +
text-shadow: 1px 1px 1px rgba(0,0,0,.6);
 +
 
 +
-webkit-transition: color .2s ease-in-out;
 +
-moz-transition: color .2s ease-in-out;
 +
-o-transition: color .2s ease-in-out;
 +
-ms-transition: color .2s ease-in-out;
 +
transition: color .2s ease-in-out;
 +
}
 +
 
 +
.menu li:first-child a { border-left: none; }
 +
.menu li:last-child a{ border-right: none; }
 +
 
 +
.menu li:hover > a { color: #F29661; }
 +
 
 +
/* Sub Menu */
 +
 
 +
.menu ul {
 +
position: absolute;
 +
top: 50px;
 +
 +
left: 0px;
 +
 
 +
padding-right: 10px;
 +
 
 +
opacity: 0;
 +
 +
background: #1f2024;
 +
 
 +
-webkit-border-radius: 0 0 5px 5px;
 +
-moz-border-radius: 0 0 5px 5px;
 +
border-radius: 0 0 5px 5px;
 +
 
 +
-webkit-transition: opacity .25s ease .1s;
 +
-moz-transition: opacity .25s ease .1s;
 +
-o-transition: opacity .25s ease .1s;
 +
-ms-transition: opacity .25s ease .1s;
 +
transition: opacity .25s ease .1s;
 +
}
 +
 
 +
.menu li:hover > ul { opacity: 1; }
 +
 
 +
.menu ul li {
 +
height: 0;
 +
overflow: hidden;
 +
padding: 0px;
 +
 
 +
-webkit-transition: height .25s ease .1s;
 +
-moz-transition: height .25s ease .1s;
 +
-o-transition: height .25s ease .1s;
 +
-ms-transition: height .25s ease .1s;
 +
transition: height .25s ease .1s;
 +
}
 +
 
 +
.menu li:hover > ul li {
 +
height: 40px;
 +
overflow: visible;
 +
padding: 0;
 +
}
 +
 
 +
.menu ul li a {
 +
width: 100px;
 +
padding: 4px 0 4px 40px;
 +
margin: 0;
 +
 
 +
border: none;
 +
border-bottom: 1px solid #353539;
 +
}
 +
 
 +
.menu ul li:last-child a { border: none; }
 +
 
 +
/* Icons */
 +
 
 +
.menu a.documents { background: url(docs.png) no-repeat 6px center; }
 +
.menu a.messages { background: url(bubble.png) no-repeat 6px center; }
 +
.menu a.signout { background: url(arrow.png) no-repeat 6px center; }
 +
 
 +
 
 +
ul.menu { margin: 0px auto 0 auto; }
 +
</style>
 +
 
 +
 
 +
<!-- logo -->
 +
 
 +
<!-- <header id="header" >  -->
 +
 +
<div  id="logo" align="center"> <!-- Logo -->
 +
 +
<img height="250"  src="https://static.igem.org/mediawiki/2013/thumb/7/70/Logo_kaist.png/800px-Logo_kaist.png" alt=""/>
 +
 +
 +
</div>
 +
 +
 
 +
<!-- menu bar -->
 +
<div>
 +
<div id="bar">
 +
 +
<ul class="menu" >
 +
 
 +
<li><a href="#">Home</a></li>
 +
<li><a href="#">Team</a></li>
 +
<li><a href="#">Project</a>
 +
 
 +
<!-- <ul>
 +
<li><a href="#" class="documents">Documents</a></li>
 +
<li><a href="#" class="messages">Messages</a></li>
 +
<li><a href="#" class="signout">Sign Out</a></li>
 +
</ul>
 +
 +
-->
 +
 
 +
</li>
 +
<li><a href="#">Labnote</a></li>
 +
<li><a href="#">Human Practice</a></li>
 +
<li><a href="#">Safety</a></li>
 +
 
 +
</ul> <!-- end .menu -->
 +
</div>
 +
</div>
 +
      <!-- </header> -->
 +
 
 +
 
 +
 
 +
<body >
 +
 
 +
<div id="page-wrapper" class="raw">
 +
<div class="5grid-layout">
 +
 
 +
 
 +
<!--
 +
<div id="feature-content">
 +
<section>
 +
<h2>RAPTOR</h2>
 +
</section>
 +
 
 +
 
 +
<div class="row">
 +
<div class="12u">
 +
<div class="row">
 +
<div class="6u">
 +
<section id="content">
 +
<div class="image-style1"><a href="#"><iframe &autoplay=1 width="570" height="315" src="//www.youtube.com/embed/wEwxiU1PP9Y" frameborder="0" allowfullscreen></iframe></a></div>
 +
                            </section>
 +
</div>
 +
<div class="3u">
 +
<section id = "sidebar">
 +
<div class="12u">
 +
<p>KAIST_Korea</p>
 +
</div>
 +
<p class="button-style"><a href="#">GO TO ABSTRACT</a></p>
 +
</section>
 +
</div>
 +
</div>
 +
</div>
 +
</div>
 +
</div>
 +
       
 +
-->   
 +
<div id="page">
 +
<div class="row">
 +
<div class="12u">
 +
<div class="row">
 +
<div class="8u">
 +
<section id="content">
 +
<h2>Introduce My team project RAPTOR.</h2>
 +
 +
<p><a href="#"><img src="images/pics02.jpg" alt=""></a></p>
 +
<p>The widely used gene knock-out strategies are based upon a mere [on-off] control and more complex regulation is impossible. On the other hand, knock-down strategies are more versatile in usage but the current techniques are vastly laborious for systematic control and pose difficulty in multiple targeting because of the intricate design and scar accumulation.
 +
iGEM KAIST 2013 seeks to take the yet-to-be-perfected genetic regulation technology to a new level: The RAPTOR (RNA Associated Prokaryotic Transcript Optimization with CRISPR) technology. RAPTOR uses CRISPR type III system for gene regulation. CRISPR type III targets and cleaves specific mRNA sequences through complementary binding of crRNA and nuclease activity of Cmr protein complex. RAPTOR exploits this nature of CRISPR for systematically down regulating the mRNA level of specific genes.
 +
Due to the characteristics of RAPTOR, one of the most useful applications of this technology can be biosynthesis pathway regulation. Programmed crRNA expression allows fine-tuning of target mRNA expression levels and can precisely regulate enzyme concentrations. Not only fine-tuning but multiplex engineering is also possible through simultaneous expression of different crRNAs. Thus, multiple enzymes can be targeted in pathway control.
 +
As a proof of concept we sought to regulate the lycopene pathway that is incorporated into the genome of Escherichia coli. The efflux of lycopene precursors is optimally reduced through lowering the mRNA levels of enzymes that synthesize non-lycopene end products. Through observation of increased lycopene yield in the E.coli, potentiality of RAPTOR technology can be validated.
 +
                                <br><br><br><br><br><br><br><br>
 +
</section>
 +
</div>
 +
<!--
 +
<div class="4u">
 +
<section id="sidebar">
 +
<h2>What is CRISPR?</h2>
 +
<p class="subtitle"></p>
 +
<p>
 +
                                <br><br></p>
 +
 +
</section>
 +
</div>
 +
-->
 +
</div>
 +
</div>
 +
</div>
 +
</div>
 +
</div>
 +
</div>
 +
</body>
 +
<!--<div id="footer-wrapper">
 +
<div id="footer-content" class="5grid-layout">
 +
<div class="row">
 +
 +
<div class="3u">
 +
 +
</div>
 +
<div class="6u">
 +
<section>
 +
<h2>footer site</h2>
 +
<p>iGEM logo </p>
 +
 +
</section>
 +
</div>
 +
</div>
 +
</div>
 +
</div> -->
 +
<div class="5grid-layout">
 +
<div id="copyright">
 +
<section>
 +
<p>&copy; Your Site Name | Images: <a href="http://fotogrph.com/">Fotogrph</a> | Design: <a href="http://html5templates.com/">HTML5Templates.com</a></p>
 +
</section>
 +
</div>
 +
</div>
 +
 
</html>
</html>

Revision as of 13:39, 15 August 2013

<!DOCTYPE HTML> iGEM Team : KAIST_Korea

Introduce My team project RAPTOR.

The widely used gene knock-out strategies are based upon a mere [on-off] control and more complex regulation is impossible. On the other hand, knock-down strategies are more versatile in usage but the current techniques are vastly laborious for systematic control and pose difficulty in multiple targeting because of the intricate design and scar accumulation. iGEM KAIST 2013 seeks to take the yet-to-be-perfected genetic regulation technology to a new level: The RAPTOR (RNA Associated Prokaryotic Transcript Optimization with CRISPR) technology. RAPTOR uses CRISPR type III system for gene regulation. CRISPR type III targets and cleaves specific mRNA sequences through complementary binding of crRNA and nuclease activity of Cmr protein complex. RAPTOR exploits this nature of CRISPR for systematically down regulating the mRNA level of specific genes. Due to the characteristics of RAPTOR, one of the most useful applications of this technology can be biosynthesis pathway regulation. Programmed crRNA expression allows fine-tuning of target mRNA expression levels and can precisely regulate enzyme concentrations. Not only fine-tuning but multiplex engineering is also possible through simultaneous expression of different crRNAs. Thus, multiple enzymes can be targeted in pathway control. As a proof of concept we sought to regulate the lycopene pathway that is incorporated into the genome of Escherichia coli. The efflux of lycopene precursors is optimally reduced through lowering the mRNA levels of enzymes that synthesize non-lycopene end products. Through observation of increased lycopene yield in the E.coli, potentiality of RAPTOR technology can be validated.